We found that the combined DC101 and anti‐TGFβ1 antibody treatment significantly enhanced the intratumoral delivery of the fluorescence nanoparticles, resulting in deeper tissue penetration and a more homogeneous distribution of these particles within the tumor interstitium (Figure4a,d,e). The gene discussed is TGFB1; the disease is neoplasm.